Trials / Active Not Recruiting
Active Not RecruitingNCT06660173
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 409 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maridebart Cafraglutide | Solution for subcutaneous injection. |
| DRUG | Placebo | Solution for subcutaneous injection. |
Timeline
- Start date
- 2024-11-07
- Primary completion
- 2025-10-06
- Completion
- 2026-11-10
- First posted
- 2024-10-28
- Last updated
- 2025-11-25
Locations
96 sites across 14 countries: United States, Austria, Greece, Hong Kong, Hungary, Italy, Japan, Poland, Puerto Rico, Romania, South Korea, Spain, Sweden, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06660173. Inclusion in this directory is not an endorsement.